Key Points
- COO Anish Patel sold 48,300 shares for $1,351,917 at an average price of $27.99 on Jan. 9, cutting his stake by 18.34% to 215,011 shares (about $6.02M).
- Other insiders—including CEO Joseph Lyssikatos and Director Richard Heyman—have also sold large tranches recently, adding to insider supply that could pressure the stock despite short‑term gains.
- ELVN traded up ~2.9% on the day; the company has a $1.53B market cap, a 12‑month range of $13.30–$29.98, and a consensus analyst rating of "Moderate Buy" with an average $41 price target.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 48,300 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the transaction, the chief operating officer directly owned 215,011 shares of the company's stock, valued at $6,018,157.89. This represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Anish Patel also recently made the following trade(s):
- On Monday, December 8th, Anish Patel sold 6,663 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.02, for a total value of $140,056.26.
- On Friday, November 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $17.40, for a total value of $116,005.80.
Enliven Therapeutics Trading Up 2.9%
Shares of ELVN stock opened at $25.75 on Wednesday. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $29.98. The stock has a market cap of $1.53 billion, a P/E ratio of -13.99 and a beta of 0.41. The stock has a 50 day moving average of $19.31 and a 200 day moving average of $20.01.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.11. On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.
Enliven Therapeutics News Roundup
Here are the key news stories impacting Enliven Therapeutics this week:
- Positive Sentiment: Technical/momentum signal—MSN highlighted Enliven as having rising relative price strength, a factor that can attract momentum traders and institutional interest. MSN Article
- Positive Sentiment: Analyst/consensus support—coverage shows a consensus of "Moderate Buy" with a ~$41 average price target, which can buttress demand from investors seeking upside relative to current levels. MarketBeat Coverage
- Neutral Sentiment: Market commentary—A recent Seeking Alpha piece warned to remain cautious despite upcoming data events; it’s not a clear buy/sell signal but may temper enthusiasm. Seeking Alpha
- Neutral Sentiment: Short-interest reporting is anomalous (a zero-share reading reported), which provides no clear bearish crowding signal and is therefore inconclusive for explaining today's move.
- Negative Sentiment: Major insider selling—CEO/insider Joseph P. Lyssikatos sold large blocks (41,302 shares at ~$24.05 and 91,198 shares at ~$27.22), raising supply and potentially weighing on price. SEC Filing
- Negative Sentiment: Additional insider exits—COO Anish Patel sold 48,300 shares (~$28 avg) and Director Richard Heyman sold multiple tranches (~13,920 shares across Jan 8–9), adding to the volume of insider supply. Patel SEC Filing Heyman SEC Filing
Wall Street Analyst Weigh In
ELVN has been the subject of a number of analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised Enliven Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, November 15th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $41.00.
Read Our Latest Stock Report on ELVN
Institutional Trading of Enliven Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its holdings in Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock worth $4,167,000 after buying an additional 80,506 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of Enliven Therapeutics in the second quarter worth approximately $8,024,000. Geode Capital Management LLC increased its position in shares of Enliven Therapeutics by 7.8% during the second quarter. Geode Capital Management LLC now owns 882,753 shares of the company's stock worth $17,711,000 after purchasing an additional 63,580 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company's stock worth $8,631,000 after purchasing an additional 410,034 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Enliven Therapeutics by 177.4% in the 2nd quarter. SG Americas Securities LLC now owns 36,373 shares of the company's stock valued at $730,000 after purchasing an additional 23,261 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
